Compare
UL Solutions Inc. vs NeoGenomics Inc vs 20/20 Biolabs, Inc.
| Latest fiscal year | UL Solutions Inc. ULS | NeoGenomics Inc NEO | 20/20 Biolabs, Inc. AIDX |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.05B | $727.33M | $2.05M |
| Revenue growth (YoY) | +6.4% | +10.1% | +16.7% |
| Gross margin | 49.5% (computed) | 43.2% | 29.6% |
| Operating margin | 17.1% | -15.9% | -162.9% |
| Net margin | 10.6% | -14.9% | -182.8% |
| Net income | $325.00M | -$108.03M | -$3.74M |
| EPS (Diluted) | $1.60 | n/a | -$0.76 |
| Operating cash flow | $600.00M | $5.23M | -$1.92M |
| Free cash flow | $403.00M | -$21.78M | n/a |
| Cash & equivalents | $295.00M | $159.62M | $1.03M |
| Total assets | $2.92B | $1.36B | $4.14M |
| Total liabilities | $1.63B | $523.27M | $4.16M |
| Shareholders' equity | $1.29B | $836.56M | -$19.2K |
| Return on year-end equity | 25.1% | -12.9% | n/a |
| Shares outstanding | 201.03M | 128.15M | 5.44M |
Revenue, most recent five fiscal years
| Fiscal year | UL Solutions Inc. | NeoGenomics Inc | 20/20 Biolabs, Inc. |
|---|---|---|---|
| Latest | $3.05B Ended 2025-12-31 | $727.33M Ended 2025-12-31 | $2.05M Ended 2025-12-31 |
| 1 year earlier | $2.87B Ended 2024-12-31 | $660.57M Ended 2024-12-31 | $1.75M Ended 2024-12-31 |
| 2 years earlier | $2.68B Ended 2023-12-31 | $591.64M Ended 2023-12-31 | n/a |
| 3 years earlier | $2.52B Ended 2022-12-31 | $509.73M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $484.33M Ended 2021-12-31 | n/a |